GPT and Hyperglycemia: Although a reliable endpoint that can effectively predict the outcome of patients is still lacking, most of the ongoing NAFLD clinical trials set the markers for liver injury (ALT and AST), lipid metabolism (TG, TC, HDL, and LDL), and hyperglycemia (fasting blood glucose) as primary outcomes.